Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study to Investigate the Efficacy and Safety of Pre-emptive Cytomegalovirus Adoptive Cellular Therapy in Patients Receiving Allogeneic Haematopoietic Stem Cell Transplant From an Unrelated Donor

NCT01220895 is registered in ClinicalTrials.gov with Cell Medica Ltd as lead sponsor.

NCT NCT01220895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01220895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study to Investigate the Efficacy and Safety of Pre-emptive Cytomegalovirus Adoptive Cellular Therapy in Patients Receiving Allogeneic Haematopoietic Stem Cell Transplant From an Unrelated Donor
Lead sponsor
Cell Medica Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
January 31, 2014
Enrollment
52 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infection